Today's Globe: DDT and cancer, Joslin building, Children's addition, Rituxan and lupus, heparin hearing, FDA rejections, Albert Hoffman

A chemical that comes from the pesticide DDT may raise a man's risk of developing testicular cancer, US researchers said yesterday.

The Boston Redevelopment Authority board unanimously approved a 335,600-square-foot research and medical building on the Joslin Diabetes Center block of the Longwood Medical Area.

The main building of Children's Hospital Boston, in the Longwood Medical Area, will grow by two floors, including 60,000 square feet of space under a plan unanimously approved by the BRA (second item).

Genentech Inc. and Biogen Idec Inc.'s cancer drug Rituxan failed in a study as a treatment for lupus (fifth item).

Johanna Marie Staples (left), the widow of a man who died after receiving contaminated heparin told a congressional subcommittee yesterday "we have a false sense of security" in a land where people expect to be protected and safe.

The Food and Drug Administration ended last week and started this one by rejecting two potential blockbuster cholesterol drugs, leaving three drug makers reeling and Wall Street wondering if tougher approval standards are here.

Albert Hofmann (left), the Swiss chemist who discovered LSD and thereby gave the psychedelic generation the pharmaceutical vehicle to turn on, tune in, and drop out, has died. He was 102.